Glenmark begins Ph I of Xolair biosimilar

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) began a Phase I trial of GBR 310, a proposed biosimilar of Xolair omalizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). T...